Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

HIV Rapid Test Kits Market - Trends and Forecasts by Technavio

Technavio Research
Posted on: 04 Oct 17

Technavio’s latest report on the global human immunodeficiency virus (HIV) rapid test kits marketprovides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

This press release features multimedia. View the full release here:

Technavio has published a new report on the global human immunodeficiency virus (HIV) rapid test kits market from 2017-2021. (Graphic: Business Wire)

The global HIV rapid test kits market will grow at a moderate pace during the forecast period. The rapid testing methods monitor critical control points in real time, thereby have reduced the turn-around-time (TAT) of disease identification. Rapid test kits improve the manufacturing process, ensure product safety, and decrease the overall cost. Owing to low-cost and better efficacy, regulatory bodies such as the US FDA, European Medicines Agency (EMA), Australian Therapeutic Goods Administration (TGA), Japanese pharmaceuticals, and regulatory bodies of other countries encourage the adoption of rapid HIV testing methods.

Srinivas Sashidhar, a lead analyst from Technavio, specializing in research on in-vitro diagnostics sector, says, “Many campaigns have been organized by governments to educate people about HIV, AIDS, and the advantages of HIV rapid testing kits. Such initiatives increase the demand for HIV rapid test kits. For instance, the US government along with the CDC developed HIV prevention plans for HIV affected population.”

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The top three emerging trends driving the global HIV rapid test kits marketaccording to Technavio research analysts are:

  • Growing preference for self-testing
  • Increase in testing programs to prove the accuracy of rapid test kits
  • Growth in campaigns to educate people about HIV

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Growing preference for self-testing

HIV self-testing in home setting only marks the presence of HIV-1/2 antibodies or the HIV-1 p24 antigen; it does not provide a diagnosis. The self-testing kit has an inbuilt control line, which makes the performance of the test accurate and reliable. The increasing preference for the self-testing procedure will drive the adoption of the HIV rapid test kits among people.

“The U.S. Agency for International Development approved Chembio Diagnostic Systems' DPP HIV 1/2 Assay in February 2017. This product is CLIA-waived and offers 95% specificity and sensitivity. It produces result within 10-25 minutes for blood detection and oral detection it takes 25-40 minutes,” according to Srinivas.

Increase in testing programs to prove the accuracy of rapid test kits

The increasing testing programs by the vendors will prove the accuracy and effectivity of the product, which, in turn, will attract the end-users. For instance, in April 2016, Alere in association with the CDC formed a testing program for its rapid test kit Alere Determine HIV-1/2 Ag/Ab Combo. The product can detect HIV-1 p24 antigen and HIV-1 and HIV-2 antibodies.

A study conducted by the CDC in April 2016 revealed that Determine Combo by Alere can detect infection within 1-2 weeks by comparing it with all other FDA-approved tests on the same plasma specimens, HIV-1 p24 antigen, and HIV-1 and HIV-2 antibodies. This reduces TAT, which helps in providing early treatment to the patients affected by HIV.

Growth in campaigns to educate people about HIV

In April 2017, the campaign, #Live2LUV helped in promoting education on sexual wellness which included HIV among the young population of South-East Asian countries. The organizations such as UNAIDS in association with Youth Lead and Youth Voices Count, the United Nations Children’s Fund and the United Nations Population Fund launched a four days campaign in association with the Association of Southeast Asian Nations (ASEAN) Youth Summit in the Philippines.

In APAC, young people account for 37% of new HIV infections. Data show that young people from key populations are at even higher risk of HIV infection than their older counterparts. For example, in Thailand, among young gay men and other men who have sex with men HIV prevalence is 11%, compared with 8.3% among gay men and other men who have sex with men who are 25 years and older. Therefore, it will help in promoting education about HIV.

The key vendors are as follows:

  • F. Hoffmann-La Roche
  • Alere

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at

View source version on

Business Wire

Last updated on: 04/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.